POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing rad...

Related Keywords

Sydney ,New South Wales ,Australia ,Andrew Adamovich ,Daniel Pearlstein ,Joe Mccann ,Biopharma Global Inc ,Globenewswire Inc ,Nasdaq ,Chief Executive Officer ,Targeted Alpha Therapies ,Targeted Alpha Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Relations Contact ,Cell Contact ,